Table 3.
Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and quality of life survey results for patients with recessive dystrophic epidermolysis bullosa participating in a trial of continuous and biweekly intravenous gentamicin
| Clinical score | Timepoint | PT1 | PT2 | PT3 | PT2* | PT3* |
|---|---|---|---|---|---|---|
| EBDASI total score (activity, damage) | Day 0 | 47, 109 | 66, 135 | 23, 107 | 52, 148 | 25, 126 |
| 1 month | 27, 136 | 52, 135 | 20, 109 | 64, 141 | 22, 121 | |
| 3 month | 45, 118 | 22, 139 | 17, 109 | 43, 144 | 22, 110 | |
| 6 month | 34, 121 | 43, 121 | 25, 126 | 60, 156 | 26, 117 | |
| Skindex-16: Symptoms | Day 0 | 13 | 15 | 15 | 16 | 6 |
| 1 month | 1 | 12 | 9 | 10 | 4 | |
| 3 month | 4 | 9 | 4 | 10 | 6 | |
| 6 month | 0 | 10 | 6 | 8 | 8 | |
| Skindex-16: Emotions | Day 0 | 2 | 6 | 34 | 6 | 12 |
| 1 month | 1 | 2 | 25 | 0 | 12 | |
| 3 month | 1 | 3 | 17 | 1 | 12 | |
| 6 month | 0 | 2 | 12 | 1 | 17 | |
| Skindex-16: Functioning | Day 0 | 2 | 1 | 8 | 4 | 5 |
| 1 month | 0 | 1 | 5 | 1 | 7 | |
| 3 month | 0 | 2 | 5 | 2 | 5 | |
| 6 month | 0 | 4 | 5 | 2 | 5 |
Patients 1–3 (PT1–PT3) participated in the continuous schedule part of the trial. Later, PT2 and PT3 joined the biweekly schedule part of the trial (denoted as PT2* and PT3*).